DCM
RDHL

DAFNA Capital Management’s Redhill Biopharma RDHL Stock Holding History

DAFNA Capital Management’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-456
Closed -$3.14M – 85
2021
Q2 		$3.14M Hold
456
– – 0.66% 38
2021
Q1 		$3.34M Buy
+456
New +$3.83M 0.79% 32
2018
Q1 		– Sell
-35
Closed -$180K – 78
2017
Q4 		$180K Buy
+35
New +$236K 0.1% 69

Other funds holding RDHL

DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

DAFNA Capital Management's RDHL Position: Q3 2021 in Review

DAFNA Capital Management sold out of Redhill Biopharma (RDHL) in Q3 2021, closing a stake of 456 shares — an estimated $3.14M sold.

DAFNA Capital Management first reported a position in RDHL in Q4 2017 and held it in 3 quarters. The position peaked at $3.34M in Q1 2021. 53 funds tracked by Wall St. Rank hold RDHL as of Q3 2021.

  • DAFNA Capital Management reported no remaining Redhill Biopharma position as of Q3 2021 after selling out during the quarter.
  • DAFNA Capital Management sold 456 Redhill Biopharma shares in Q3 2021, an estimated $3.14M.
  • DAFNA Capital Management first reported a position in Redhill Biopharma in Q4 2017 and held it in 3 quarters.
  • DAFNA Capital Management's Redhill Biopharma position peaked at $3.34M in Q1 2021.
  • 53 funds tracked by Wall St. Rank held Redhill Biopharma as of Q3 2021.

Based on DAFNA Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.